Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Hidden Impacts of Peritoneal Dialysis on the Endocrine System

Ueno H., Ueta Y., Koga JI., Maruyama T., Miyamoto T., Kataoka M.

Narrative Review on Scar, published in Life (Basel) (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Life (Basel) (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41157262
PMCID
PMC12565292
DOI
10.3390/life15101588

Abstract (original English)

Peritoneal dialysis (PD) is a widely used renal replacement therapy in which hyperosmolar solutions are instilled into the abdominal cavity to facilitate the removal of excess water, electrolytes, and metabolic waste products. During PD treatment, homeostasis is maintained through adaptive responses of the neuroendocrine system to high glucose exposure, changes in circulating blood volume, and shifts in electrolyte balance. Clinical observations and limited experimental studies suggest that these neurohormonal dynamics may influence both the complications and therapeutic efficacy of PD. However, systematic investigations remain scarce, largely because hormonal and neural responses are highly dynamic, involve complex interactions, and are substantially influenced by individual patient characteristics. In this review, we synthesize current clinical and experimental evidence linking PD-related complications with hidden hormone dynamics, with particular emphasis on hypothalamic hormones such as arginine vasopressin. We also discuss how the biocompatibility of PD solutions-traditionally assessed by their effects on peritoneal mesothelial cells-could be reconsidered when neuroendocrine aspects are taken into account. We propose that integrating both clinical insights and emerging basic research will provide a more comprehensive understanding of neuroendocrine regulation in PD and may

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research